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S U M M A R Y
Hospital and national committees often focus on drug acquisition costs when taking decisions on the use
of new drugs, but antimicrobial agent costs represent a minor part of the bill compared with the indirect
costs of hospitalization or loss in days of productivity in working people. Although reducing the length of
stay should be a main priority in the USA due to the indirect costs associated with hospitalization,
adverse events, such as renal failure, have a major impact on healthcare resource use and costs. However,
where hospital reimbursement is based on closed budgets, the paradox is that treating more patients due
to reductions in length of stay may not be attractive to administrators, because the cost of discharging
patients earlier is not compensated by the increase in severity in replacing stays of newer patient
admissions. Furthermore, neuropsychological, physical, and immune impairment caused by sepsis has
an extreme impact on long-term quality of patient life and health care resource consumption. Future
research is warranted to further explore the potential impact of newer therapies for infections and
sepsis, taking into account the costs of complications, effects on long-term quality of life, and particularly
an international perspective, which requires customization for each national payer’s system.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idPatients with infections caused by resistant bacteria have
increased mortality, hospital length of stay (LOS), and healthcare
costs. Results from the Extended Prevalence of Infection in the ICU
(EPIC II) study suggest that the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) and multidrug-resistant (MDR)
Gram-negative organisms is higher in Asian than in American
and European intensive care units (ICUs).1 However, it appears that
few studies have compared the economic outcomes associated
with therapy in patients with nosocomial pneumonia (NP) from
different geographical areas.
To address this gap, a study was recently performed to assess
healthcare resource use (HCRU) and costs associated with MRSA NP
from a Spanish payer’s perspective.2 The results showed that there
were no signiﬁcant differences in treatment costs between patients
treated with linezolid (s17 782) and those treated with vancomy-
cin (s17 423). The signiﬁcantly higher drug cost for linezolid
therapy compared to vancomycin therapy may have been partially
offset by fewer renal failure events or shorter hospitalizations. Bed* Corresponding author. Tel.: +34 932746209.
E-mail address: jrello@crips.es (J. Rello).
http://dx.doi.org/10.1016/j.ijid.2016.08.004
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).costs were found to be the main cost driver, with ICU costs
constituting the highest proportion; this is not the case in China.
Similar studies have evaluated the treatment costs of linezolid
vs. vancomycin in patients with MRSA NP in the USA3 and China.4
When these studies were compared, it was unclear whether the
conclusions from the USA study would remain robust when the
Spanish or Chinese costs were applied, due to fundamental
differences in each country’s healthcare system. In Spain (and
other European countries), healthcare is universally covered and
fully funded from taxes obtained from the citizens. This means that
health services are mostly free of charge at the point of delivery. In
contrast, healthcare in the USA is not universally covered; there is
no single payer for healthcare.
China also has a different healthcare system compared to most
Western countries, adopting increasing health care privatization
and decentralization from the central government to provincial
and local authorities.5 Public hospitals in China are a critical part of
the health system, accounting for 89% of total beds and 92% of
hospital admissions. From the day of foundation of the Peoples’
Republic of China to the early 1980s, local governments were
responsible for the total ﬁnancing of public health. In the late
1980s, reforms were introduced aimed at limiting governmentciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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as low as 7% of hospital revenues), and public hospitals were
permitted to retain proﬁts from sales of medicines (15% of total
sales of medicines, becoming the main revenue source of public
hospitals) and diagnostic examinations. However, the government
continued to control the numbers of staff and beds, with very low
ﬁxed bed charges and medical and nursing services charges. Under
this health policy, a huge increase in the costs of medicine and
diagnostic tests was noticed during the last 20 years, but no
increase in bed charges or medical labor costs. As the income from
medical labor is low, the total number of doctors and nurses is
much lower than required per bed in public hospitals. In 2009,
another round of reforms was announced by the government
aimed at increasing efﬁcacy and reducing total costs. However, the
goal needs further input from the government, as well as the
reform of health insurance and payment systems. Since 2010,Table 1
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MRSA, methicillin-resistant Staphylococcus aureus; HCRU, healthcare resource use; NP,
a More details about the methods (including outcomes, statistical analyses, and cost-e
China studies.14,25.
b The cost data in the USA ($) and China (¥) studies were converted to equivalent cost i
as the Chinese and Spanish studies (Consumer Price Index for medical care items: http://
equivalent Euro. The currency conversion rates ($1 = s0.92, ¥1 = s0.14) 
converter?a=1&from=EUR&to=USD, accessed December 8, 2015).
Costs for linezolid vs. vancomycin converted to Euro: US s42,921 vs. s42,819, p = 0.96;
patients who developed renal failure vs. those who did not converted to Euro: US s49,8
s17,388, p = 0.14. Cost-effectiveness ratio converted to Euro: US s15,751 (95% CI s6
c The China study reported the cost data for four major cities in China; the city of Nan
among the four cities.
d The median estimate of the cost-effectiveness ratio is provided.medical services and pharmaceutical sales have been separated in
some pilot hospitals, with more insurance reimbursements for
adjusted medical services (not including bed charges).
Although the main conclusions of the European study are
consistent with the economic analysis from the USA, there are
some notable differences from the Spanish perspective.2,3 A key
difference in the ﬁndings was that the total costs and cost
components were lower from the Spanish payer’s perspective
compared to the USA (Table 1). This is consistent with the total
medical expenditure data in Organization for Economic Coopera-
tion and Development (OECD) countries: total medical expendi-
ture in the USA was two to three-fold higher per capita than in
most other OECD countries.6 Speciﬁcally, in 2014 the cost was
estimated to be $3053 (private) and $2131 (public) per capita in
Spain and $9024 (private) and $4448 (public) in the USA.6 This is
also consistent with the ﬁndings of the ZEPHyR trial, in which iterformed in the USA, China, and Spain (adapted from Rello et al.2)
n et al., 20154 Rello et al., 20162
ina Spain
centralization from central
vernment to provincial and local
thorities
Government as the single payer
(universal coverage)
 assess cost-effectiveness of linezolid
 vancomycin in treating MRSA NP in
ina and the impact of renal failure on
RU and costs
To assess the HCRU and costs for
treating MRSA NP in hospitalized adults
using linezolid or vancomycin, from a
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evaluated the effect of renal failure on
costs
e cost analyses were performed for
r selected large cities in China,
ich are economically and
ographically diverse, representing
 north, south, east, and west of the
ntry; the unit costs were obtained
m physician interviews (expert
inions)
Healthcare costs were calculated by
multiplying observed HCRU (MV, bed-
days by type, drug, and dialysis) by
their own unit costs, respectively; the
drug unit costs were obtained from
Botplus-Portalfarma, and other medical
service unit costs were obtained from
the Oblikue database
 signiﬁcant difference in the costs
tween patients treated with linezolid
d vancomycin
anjingc: ¥82 383 vs. ¥80 799, p = 0.70)
No signiﬁcant difference in the costs
between patients treated with linezolid
and vancomycin
(s17 782 vs. s17 423, p = 0.51)
tients who developed renal failure
d a higher cost than those who did
t
anjing: ¥100 449 vs. ¥74 944,
 0.01)
Patients who developed renal failure
had a higher cost than those who did
not
(s19 626 vs. s17 388, p = 0.14)
njing: ¥15 904 (95% CI -¥161 935 to
14 987)
The cost-effectiveness ratio may be
higher in the study from Spain than in
the USA or China studies, since the
incremental cost between treatments
was the highest in Spain, although the
incremental success rate remained the
same across the three studies
ezolid was more cost-effective than
ncomycin in treating MRSA NP from a
inese payer’s perspective
ezolid was associated with a
niﬁcantly lower rate of renal failure
n vancomycin
From a Spanish perspective, there were
no statistically signiﬁcant differences in
total costs between the linezolid and
vancomycin cohorts
The drug cost of linezolid was partially
offset by fewer renal failure events
 nosocomial pneumonia; MV, mechanical ventilation; CI, conﬁdence interval..
ffectiveness techniques) and unit cost values can be found in the published USA and
n Euro (s). The cost data in the USA study were inﬂated to the same year (year 2012)
data.bls.gov/cgi-bin/surveymost, accessed December 8, 2015) and then converted to
were obtained from Google Finance (https://www.google.com/ﬁnance/
 China s11,534 vs. s11,312, p = 0.70; Spain s17 782 vs. s17 423, p = 0.51. Costs for
38 vs. s42,131, p = 0.046; China s14,063 vs. s10,492, p = 0.002; Spain: s19,626 vs.
5,444 to s156,864); China s2227 (95% CI s22,671 to s44,09).
jing was selected for this table because the unit cost for Nanjing was in the middle
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an over 40% longer LOS than those in the USA (63%) (mean LOS
23 vs. 16 days), but lower total hospitalization costs for both
treatment groups.7 The incremental difference in total cost
between the linezolid and vancomycin groups was the highest
in the European study2 (s359), followed by that from China4
(¥1584 = s222)4 and that from the USA ($107 = s102).3
Although some pharmaco-economic data regarding the selec-
tion of different antibiotics are available, most data come from the
USA. Data on the economic burden associated with MRSA
pneumonia in Europe are limited and vary widely across studies.
Results from a Spanish study evaluating data from 27 hospitals
found that MRSA bacteremia was associated with a mean inpatient
LOS of 25 days, an ICU admission rate of 28.7%, and treatment costs
of s11 884 per episode.8 A European study (EUVAP) concluded
that patients who received inappropriate treatment had an ICU
stay approximately 6 days longer than those who received
appropriate empiric treatment.9 Decision-makers may use this
information to justify the need for strategies aimed at the
prevention of MDR and pneumonia, and clinicians may use this
information to understand the economic burden associated with
antibiotic treatment strategies.
Hospital and national committees often focus on drug acquisi-
tion costs when taking decisions on the use of new drugs, but
antimicrobial agent costs represent a minor part of the bill
compared with the indirect costs of hospitalization or loss in days
of productivity in working people. (In an ongoing analysis of the
economic costs of hospitalized community-acquired pneumonia, it
was found that the cost of the antimicrobial agent was about 20% of
the total cost; data not reported.) Of note, updated data on the
economic burden associated with antibiotic treatment in patients
with NP in the USA cannot be generalized. In particular, data
derived from practice in the USA, where private practice reports
double the costs of public practice,6 cannot be translated to
countries with a national health service.
Although reducing the LOS should be a main priority in the USA
due to the indirect costs associated with hospitalization, adverse
events, such as renal failure, have a major impact on HCRU and
costs. For example, in 2005, an increase in serum creatinine
0.5 mg/dl was associated with nearly $7500 in excess hospital
costs added to the bill.10 It should be emphasized that the high
drug acquisition costs of newer antibiotics are partially offset by
fewer complications, such as acute kidney injury events, which
impact ICU, hospital bed, and renal replacement therapy costs. The
potential consequences of developing renal failure include an
increase in the odds of death, 4–5 extra days of hospitalization, and
higher treatment costs.10 The renal failure rate in the ZEPHyR trial
was signiﬁcantly lower in the linezolid arm than in the vancomycin
arm (4% vs. 15%, respectively; p < 0.001).7 Although not statisti-
cally signiﬁcant due to the small cohort size (n = 43), the duration
of mechanical ventilation was 6 extra days (13.3  10.7 vs.
7.6  3.6 days), the duration of the ICU stay was 5 extra days
(14.4  10.5 vs. 9.9  6.6 days), and the duration of hospitalization
was 3 extra days (19.5  9.5 vs. 16.1  11.0 days) for patients treated
with vancomycin compared to those treated with linezolid. However,
where hospital reimbursement is based on closed budgets, the
paradox is that treating more patients due to reductions in LOS may
not be attractive for administrators, because the cost of discharging
patients earlier is not compensated by the increase in severity inreplacing stays of newer patient admissions. Furthermore, neuropsy-
chological, physical, and immune impairment caused by sepsis has an
extreme impact on long-term quality of patient life and health care
resource consumption, which makes this a ‘hidden public health
disaster’.11
Future research is warranted to further explore the potential
impact of newer therapies for infections and sepsis, taking into
account the costs of complications, effects on long-term quality of
life, and particularly an international perspective, which requires
customization for each national payer’s system (http://ec.europa.
eu/eurostat/statistics-explained/index.php/Healthcare_statistics).
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